Interleukin (IL)-17A inhibitors are indicated for the treatment of chronic plaque psoriasis and psoriatic arthritis (PsA), and they could inhibit the radiographic progression of PsA.1 However, IL-17A inhibitors might not be as effective in PsA as they are in plaque psoriasis, at least for some patients. Indeed, from January to December 2018 a total of 162 patients were treated with secukinumab
Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor-α to interleukin-17A inhibitor
Gisondi, P;GEAT, DAVIDE;Idolazzi, L;Girolomoni, G
2019-01-01
Abstract
Interleukin (IL)-17A inhibitors are indicated for the treatment of chronic plaque psoriasis and psoriatic arthritis (PsA), and they could inhibit the radiographic progression of PsA.1 However, IL-17A inhibitors might not be as effective in PsA as they are in plaque psoriasis, at least for some patients. Indeed, from January to December 2018 a total of 162 patients were treated with secukinumab
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
